Sangamo Therapeutics (SGMO) Misses Q2 EPS by 3c

Sangamo Therapeutics (NASDAQ: SGMO) reported Q2 EPS of ($0.18), $0.03 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $300 thousand versus the consensus estimate of $6.88 million.

For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.

You May Also Be Interested In

• Anthropic Signs $35b Cloud Deal With Lambda In Texas: WSJ
• Guggenheim Starts Latigo Biotherapeutics (LTGO) at Buy
• Morgan Stanley Downgrades Nordea Bank Abp (NDA:SS) (NRDBY) to Equalweight